Posted by Michael Wonder on 28 Nov 2021
Anti-cancer agent Herceptin approved for additional indication of salivary gland cancer
25 November 2021 - Herceptin has been approved as the first drug for salivary gland cancer, for which there is no established standard chemotherapy, based on a personalised medicine approach.
Chugai Pharmaceutical announced that it obtained approval from the Ministry of Health, Labour and Welfare for the anti-HER2 humanised monoclonal antibody Herceptin Injection 60 and 150 [trastuzumab] for the additional indication of advanced or recurrent HER2-positive salivary gland cancer not amenable to curative resection.
Orphan drug designation had been granted by the MHLW on 11 March 2021 for this indication.
